Carla M Bann1, Sheri E Fehnel, Dennis D Gagnon. 1. Statistics Research Division, RTI International, Research Triangle Park, North Carolina 27709-2194, USA. cmb@rti.org
Abstract
BACKGROUND: The Diabetic Foot Ulcer Scale (DFS) provides comprehensive measurement of the impact of diabetic foot ulcers on patients' QOL through self-administration of 64 items comprising 15 subscales. OBJECTIVE: To develop and evaluate a short form of the DFS (DFS-SF) to reduce patient burden and the number of outcome measures, and to improve sensitivity to change in clinical condition. METHODS: The DFS-SF was created through the analysis of data from a double-blind, placebo-controlled, randomised trial of the efficacy and safety of becaplermin (recombinant human platelet-derived growth factor BB) in the treatment of chronic, full-thickness, neuropathic, diabetic foot ulcers. Using these data, items demonstrating poor psychometric properties were eliminated. Exploratory factor analyses were then conducted to develop a new, more parsimonious scaling algorithm that optimised the internal consistency of the new subscales. Finally, data from two additional clinical trials were used to assess replicability of the DFS-SF subscale structure. RESULTS: The DFS-SF contains a total of 29 items comprising six subscales. The results of both confirmatory and exploratory factor analyses provided support for the scaling algorithm. The DFS-SF subscales showed good internal consistency, reliability and construct validity, and demonstrated sensitivity to ulcer healing. CONCLUSIONS: The results of this investigation indicate that the DFS-SF has good psychometric properties and replicability.
RCT Entities:
BACKGROUND: The Diabetic Foot Ulcer Scale (DFS) provides comprehensive measurement of the impact of diabetic foot ulcers on patients' QOL through self-administration of 64 items comprising 15 subscales. OBJECTIVE: To develop and evaluate a short form of the DFS (DFS-SF) to reduce patient burden and the number of outcome measures, and to improve sensitivity to change in clinical condition. METHODS: The DFS-SF was created through the analysis of data from a double-blind, placebo-controlled, randomised trial of the efficacy and safety of becaplermin (recombinant human platelet-derived growth factor BB) in the treatment of chronic, full-thickness, neuropathic, diabetic foot ulcers. Using these data, items demonstrating poor psychometric properties were eliminated. Exploratory factor analyses were then conducted to develop a new, more parsimonious scaling algorithm that optimised the internal consistency of the new subscales. Finally, data from two additional clinical trials were used to assess replicability of the DFS-SF subscale structure. RESULTS: The DFS-SF contains a total of 29 items comprising six subscales. The results of both confirmatory and exploratory factor analyses provided support for the scaling algorithm. The DFS-SF subscales showed good internal consistency, reliability and construct validity, and demonstrated sensitivity to ulcer healing. CONCLUSIONS: The results of this investigation indicate that the DFS-SF has good psychometric properties and replicability.
Authors: J W Meijer; J Trip; S M Jaegers; T P Links; A J Smits; J W Groothoff; W H Eisma Journal: Disabil Rehabil Date: 2001-05-20 Impact factor: 3.033
Authors: M Weinberger; M S Kirkman; G P Samsa; P A Cowper; E A Shortliffe; D L Simel; J R Feussner Journal: Med Care Date: 1994-12 Impact factor: 2.983
Authors: S Kumar; H A Ashe; L N Parnell; D J Fernando; C Tsigos; R J Young; J D Ward; A J Boulton Journal: Diabet Med Date: 1994-06 Impact factor: 4.359
Authors: Young Ho Yun; Ju Youn Jung; Jin Ah Sim; JongMog Lee; Dong-Young Noh; Wonshik Han; Kyu Joo Park; Seung-Yong Jeong; Ji Won Park; Hong-Gyun Wu; Eui Kyu Chie; Hak Jae Kim; Kyung Hae Jung; Jae-Ill Zo; Sung Kim; Jeong Eon Lee; Seok Jin Nam; Eun Sook Lee; Jae Hwan Oh; Young-Woo Kim; Young Tae Kim; Young Mog Shim Journal: Qual Life Res Date: 2017-10-30 Impact factor: 4.147
Authors: Alexander Gamus; Hanna Kaufman; Elad Keren; Gila Brandin; Daniel Peles; Gabriel Chodick Journal: Int Wound J Date: 2018-05-24 Impact factor: 3.315
Authors: Simon J Otter; Kevin Lucas; Kate Springett; Ann Moore; Kevin Davies; Liz Cheek; Adam Young; Karen Walker-Bone Journal: Clin Rheumatol Date: 2009-12-08 Impact factor: 2.980